RELATED PRODUCTS NOT AVAILABLE
true
Support
Sales
1.844.8.BD.LIFE (1.844.823.5433)
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Ordering
1.800.556.6756
BDISurgery@bd.com
Onsite Visiting
100 Crossings BoulevardWarwick, Rhode Island 02886United States
Customer Service
1.844.8.BD.LIFE (1.844.823.5433)
Monday to Friday 8:15 AM to 6:00 PM EST
1.800.531.4124
Custserv.davol@bd.com
Shipping a Product Back
100 Crossings Boulevard, Warwick, Rhode Island 02886, United States
- Overview
- Products & Accessories
- EIFU & Resources
- FAQs
A strong elastic seal where it matters most
Tridyne™ Vascular Sealant is the latest addition to the BD family of hemostasis solutions, offering cardiovascular, cardiothoracic, and vascular surgeons a unique, easy-to-use solution to reinforce aortic anastomoses and control bleeding when adjunctive measures are required. By combining a proprietary formulation of polyethelyne glycol and human serum albumin, it forms a strong, flexible seal, even in anticoagulated patients.1,2 The Tridyne™ hydrogel is designed to adhere where it should – on both tissue and grafts.*
Preclinical data demonstrates that Tridyne™ Vascular Sealant resorbs naturally to maintain its seal strength through the critical postoperative period without compromising tissue healing.2
true
Precise, controlled application—made easy
Tridyne™ Vascular Sealant provides application control without the need for pressurized gas.
The Tridyne™ applicator is designed to:
- Provide uniform, continuous coverage without clumping
- Control sealant application by varying hand pressure
- Easily transition from targeted application over the anastomosis to broader coverage to address more diffuse bleeding
Clarity and coverage
The specialized Tridyne™ formulation is transparent and forms a completely clear hydrogel at the application site. With its unique combination of clarity and coverage, Tridyne™ Vascular Sealant allows for visual confirmation of hemostasis at the anastomotic suture line—making it an ideal choice for aortic surgery.
Performance under pressure
In a prospective, randomized, controlled multicenter study, Tridyne™ Vascular Sealant outperformed Gelfoam® Plus Hemostasis Kit in several critical measures. The study included 156 patients from 18 different centers who underwent thoracic aortic surgery, with hemostasis evaluated at the aortic anastomotic suture line.1
The proven solution during aortic repair1
Tridyne™ Vascular Sealant offers surgeons a specialized, easy-to-use solution during aortic repair, with unique application control and clinically proven results.1 With its demonstrated ability to provide fast, effective control of bleeding, it’s clearly the sealant choice for aortic surgery.
* The use of Tridyne™ Vascular Sealant with ePTFE grafts or vascular patches has not been studied clinically. Preclinical data on file. Preclinical test results may not correlate to clinical performance.
1. Khoynezhad A, DelaRosa J, Moon M, et al. Facilitating Hemostasis After Proximal Aortic Surgery: Results of The PROTECT Trial. Ann Thorac Surg. 2018;105(5):1357-1364.
2. BD Inc. In vitro testing. Data on file. Preclinical test results may not correlate to clinical performance.
3. Tridyne™ Vascular Sealant is indicated for use in aortic surgery when adjunctive measures to achieve hemostasis are required by mechanically sealing areas of leakage.
4. One subject from the Gelfoam® Plus treatment group required a reoperation for aortic bleeding complications following completed surgery through 30 days.
5. Mean time to hemostasis was 2.07 minutes for the Tridyne™ Vascular Sealant treatment group and 6.3 minutes for the Gelfoam® Plus control treatment group (P < 0.0001).
Indications
Tridyne™ Vascular Sealant (Tridyne™ VS) is indicated for use in aortic surgery when adjunctive measures to achieve hemostasis are required by mechanically sealing areas of leakage.
Contraindications
Tridyne™ VS is not for intravascular use. Do not use Tridyne™ VS in patients who have a history of allergic reaction to Human Serum Albumin, Polyethylene Glycol, or other device components. Do not apply Tridyne™ VS on oxidized regenerated cellulose, absorbable gelatin sponges, or any other surface or material other than the target tissue or graft as adherence and intended outcome may be compromised. Do not use Tridyne™ VS in patients who have insufficient renal capacity for clearance of the Polyethylene Glycol load.
Warnings
Do not use Tridyne™ VS as a substitute for standard closure techniques. Excessive pressure against the vessel/graft edges or surrounding tissue during application may result in separation of the vessel/graft edges, allowing sealant into the vessel.
Do not apply Tridyne™ VS when the vessel lumen is under negative pressure to avoid product from being drawn into the vessel (e.g., avoid applying in vessels that are not pressurized).
Do not use more than 30 mL of Tridyne™ VS per patient. Do not allow non-polymerized Tridyne™ VS to contact circulating blood.
Adverse Events
In a pivotal clinical trial, approximately half of the subjects in each treatment group experienced a Serious Adverse Event while in the study (51 subjects [48.1%] treated with Tridyne™ VS, 29 subjects [58.0%] treated with Control). Three Serious Adverse Events in the treatment group were considered by the Clinical Events Committee to be possibly device-related. These Serious Adverse Events included: cerebrovascular accident and serosanguineous pericardial effusion. None of the Serious Adverse Events were unexpected given the procedures performed. The details of these clinical trial adverse events can be reviewed in the Instructions for Use supplied with the product and are also available at www.bd.com. Caution: Federal (USA) law restricts this device to sale by or on order of a licensed physician or properly licensed practitioner.
true
BD-14650
* The use of Tridyne™ Vascular Sealant with ePTFE grafts or vascular patches has not been studied clinically. Preclinical data on file. Preclinical test results may not correlate to clinical performance.
1. Khoynezhad A, DelaRosa J, Moon M, et al. Facilitating Hemostasis After Proximal Aortic Surgery: Results of The PROTECT Trial. Ann Thorac Surg. 2018;105(5):1357-1364.
2. BD Inc. In vitro testing. Data on file. Preclinical test results may not correlate to clinical performance.
3. Tridyne™ Vascular Sealant is indicated for use in aortic surgery when adjunctive measures to achieve hemostasis are required by mechanically sealing areas of leakage.
4. One subject from the Gelfoam® Plus treatment group required a reoperation for aortic bleeding complications following completed surgery through 30 days.
5. Mean time to hemostasis was 2.07 minutes for the Tridyne™ Vascular Sealant treatment group and 6.3 minutes for the Gelfoam® Plus control treatment group (P < 0.0001).
Indications
Tridyne™ Vascular Sealant (Tridyne™ VS) is indicated for use in aortic surgery when adjunctive measures to achieve hemostasis are required by mechanically sealing areas of leakage.
Contraindications
Tridyne™ VS is not for intravascular use. Do not use Tridyne™ VS in patients who have a history of allergic reaction to Human Serum Albumin, Polyethylene Glycol, or other device components. Do not apply Tridyne™ VS on oxidized regenerated cellulose, absorbable gelatin sponges, or any other surface or material other than the target tissue or graft as adherence and intended outcome may be compromised. Do not use Tridyne™ VS in patients who have insufficient renal capacity for clearance of the Polyethylene Glycol load.
Warnings
Do not use Tridyne™ VS as a substitute for standard closure techniques. Excessive pressure against the vessel/graft edges or surrounding tissue during application may result in separation of the vessel/graft edges, allowing sealant into the vessel.
Do not apply Tridyne™ VS when the vessel lumen is under negative pressure to avoid product from being drawn into the vessel (e.g., avoid applying in vessels that are not pressurized).
Do not use more than 30 mL of Tridyne™ VS per patient. Do not allow non-polymerized Tridyne™ VS to contact circulating blood.
Adverse Events
In a pivotal clinical trial, approximately half of the subjects in each treatment group experienced a Serious Adverse Event while in the study (51 subjects [48.1%] treated with Tridyne™ VS, 29 subjects [58.0%] treated with Control). Three Serious Adverse Events in the treatment group were considered by the Clinical Events Committee to be possibly device-related. These Serious Adverse Events included: cerebrovascular accident and serosanguineous pericardial effusion. None of the Serious Adverse Events were unexpected given the procedures performed. The details of these clinical trial adverse events can be reviewed in the Instructions for Use supplied with the product and are also available at www.bd.com. Caution: Federal (USA) law restricts this device to sale by or on order of a licensed physician or properly licensed practitioner.
true
BD-14650
Literature
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
Learn more
Training
BD offers training resources to help improve your clinical practices as part of our goal of advancing the world of health.
Learn more
Events
BD supports the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.
Learn more
Case Studies
BD promotes clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
Learn more
true
* The use of Tridyne™ Vascular Sealant with ePTFE grafts or vascular patches has not been studied clinically. Preclinical data on file. Preclinical test results may not correlate to clinical performance.
1. Khoynezhad A, DelaRosa J, Moon M, et al. Facilitating Hemostasis After Proximal Aortic Surgery: Results of The PROTECT Trial. Ann Thorac Surg. 2018;105(5):1357-1364.
2. BD Inc. In vitro testing. Data on file. Preclinical test results may not correlate to clinical performance.
3. Tridyne™ Vascular Sealant is indicated for use in aortic surgery when adjunctive measures to achieve hemostasis are required by mechanically sealing areas of leakage.
4. One subject from the Gelfoam® Plus treatment group required a reoperation for aortic bleeding complications following completed surgery through 30 days.
5. Mean time to hemostasis was 2.07 minutes for the Tridyne™ Vascular Sealant treatment group and 6.3 minutes for the Gelfoam® Plus control treatment group (P < 0.0001).
Indications
Tridyne™ Vascular Sealant (Tridyne™ VS) is indicated for use in aortic surgery when adjunctive measures to achieve hemostasis are required by mechanically sealing areas of leakage.
Contraindications
Tridyne™ VS is not for intravascular use. Do not use Tridyne™ VS in patients who have a history of allergic reaction to Human Serum Albumin, Polyethylene Glycol, or other device components. Do not apply Tridyne™ VS on oxidized regenerated cellulose, absorbable gelatin sponges, or any other surface or material other than the target tissue or graft as adherence and intended outcome may be compromised. Do not use Tridyne™ VS in patients who have insufficient renal capacity for clearance of the Polyethylene Glycol load.
Warnings
Do not use Tridyne™ VS as a substitute for standard closure techniques. Excessive pressure against the vessel/graft edges or surrounding tissue during application may result in separation of the vessel/graft edges, allowing sealant into the vessel.
Do not apply Tridyne™ VS when the vessel lumen is under negative pressure to avoid product from being drawn into the vessel (e.g., avoid applying in vessels that are not pressurized).
Do not use more than 30 mL of Tridyne™ VS per patient. Do not allow non-polymerized Tridyne™ VS to contact circulating blood.
Adverse Events
In a pivotal clinical trial, approximately half of the subjects in each treatment group experienced a Serious Adverse Event while in the study (51 subjects [48.1%] treated with Tridyne™ VS, 29 subjects [58.0%] treated with Control). Three Serious Adverse Events in the treatment group were considered by the Clinical Events Committee to be possibly device-related. These Serious Adverse Events included: cerebrovascular accident and serosanguineous pericardial effusion. None of the Serious Adverse Events were unexpected given the procedures performed. The details of these clinical trial adverse events can be reviewed in the Instructions for Use supplied with the product and are also available at www.bd.com. Caution: Federal (USA) law restricts this device to sale by or on order of a licensed physician or properly licensed practitioner.
true
BD-14650
Definition: A vascular sealant is a solution used to reinforce aortic anastomoses and control bleeding when adjunctive measures are required during surgery.
Yes. Tridyne™ Vascular Sealant is indicated for use in aortic surgery when additional measures are needed to achieve hemostasis. This is used to mechanically seal areas of leakage.
Yes. Tridyne™ Vascular Sealant is indicated for use in aortic surgery when additional measures are needed to achieve hemostasis. This is used to mechanically seal areas of leakage.
Tridyne™ Vascular Sealant provides application control for surgeons without the need for pressurized gas. The Tridyne™ applicator is designed in order to:
- Provide uniform coverage without any clumping
- Control all sealant application through varying levels of hand pressure
- Easily transition from targeted application to more broad coverage in order to address more diffuse bleeding
The Tridyne™ Vascular Sealant forms a strong but flexible seal, even in anticoagulated patients by combining a proprietary formulation of polyethylene glycol and human serum albumin.1,2 The Tridyne™ hydrogel is designed to adhere to both tissue and grafts.
It also offers surgeons with a specialized, and easy-to-use solution during aortic repair. It has a unique application control and has clinically proven results.1 Since TridyneTM has a demonstrated ability to provide fast and effective bleeding control, it has become an ideal sealant choice for aortic surgery.
1. Preparation Process
- Draw 2 mL of water that is sterile
- Inject the 2 mL of sterile water into the white powder cartridge
- Mix for 1-2 minutes until powder has dissolved (Tridyne™ Vascular Sealant need to be used within 20 minutes of mixing)
- Load the cartridges (Properly loaded cartridges sit flush with the end of the applicator housing)
- Insert the locking push rod (Once inserted, the push rod shouldn’t be removed)
- Express any air
- Wipe the applicator tip clean
- Attach the spray tip
2. Application Process
- Assess the aortic suture lines for any bleeding
- Rinse the area with sterile saline in order to remove any pooled blood or blood clots
- Blot the intended treatment area with a gauze or a sponge to dry it
- Don’t apply the Tridyne™ Vascular Sealant when the vessel lumen is under any negative pressure. This helps to avoid product from being drawn into the vessel (e.g., avoid applying to vessels when they are not pressurized)
- Position the applicator tip over the site you are targeting and apply pressure to the push rod in order to dispense the sealant
- Maintain firm pressure and then move the spray tip from side-to-side
- The Tridyne™ Vascular Sealant will then form a flexible hydrogel two minutes after application
BD-111509
true